Psych Congress NetworkFDA Approves Centanafadine for Pediatric and Adult ADHD

🧠 Mental Health / Behavioral Sensitivity

The FDA approved centanafadine (SIMTRIYO) for ADHD in adults and pediatric patients aged 6 years and older weighing at least 20 kg. The once-daily extended-release agent represents the first approved NDSRI mechanism for ADHD treatment.

Clinical Considerations

• Four phase 3 studies demonstrated statistically significant symptom improvements versus placebo in adults and pediatric populations.
• Treatment effects were observed as early as week 1 and maintained throughout study periods.
• Common adverse events included decreased appetite, insomnia, headache, nausea, dry mouth, abdominal pain, and rash.
• Boxed warnings address pediatric suicidal ideation and the potential for abuse, misuse, and addiction.

Practice Applications

• Recognize centanafadine introduces a novel ADHD pharmacologic mechanism.
• Monitor boxed-warning safety considerations during treatment selection.
• Interpret efficacy findings within the context of phase 3 trial populations.
• Consider individual symptom profiles when evaluating emerging treatment options.